

AMENDED

631786

AUSTRALIA

Patents Act 1990



PATENT REQUEST: STANDARD PATENT/PATENT OF ADDITION

We, being the person(s) identified below as the Applicant, request the grant of a patent to the person identified below as the Nominated Person, for an invention described in the accompanying standard complete specification.

Full application details follow.


- [71] Applicant: BIOCHEM PHARMA INC.
Address: 10900 Hamon Street, Montreal, (Quebec) H3M 3A2, Canada
- [70] Nominated Person: BIOCHEM PHARMA INC.
Address: 10900 Hamon Street, Montreal, (Quebec) H3M 3A2, Canada
- [54] Invention Title: 2-SUBSTITUTED-4-SUBSTITUTED-1,3-DIOXOLANES, SYNTHESIS AND USE THEREOF
- [72] Name(s) of actual inventor(s): BERNARD BELLEAU
DILIP DIXIT
NGHE NGUYEN-BA
- [74] Address for service in Australia
Cullen & Co.
Patent & Trade Mark Attorneys
240 Queen Street
Brisbane, Qld., 4000
Australia
- Attorney Code: CU

BASIC CONVENTION APPLICATION(S) DETAILS

- [31] Application Number 179,615
[33] Country U.S.A.
Country Code US
Date of Application 11.04.88

DATED this 2nd day of July 1992

BIOCHEM PHARMA INC.

By: 

Registered Patent Attorney

TO: THE COMMISSIONER OF PATENTS
AUSTRALIA

COMMONWEALTH OF AUSTRALIA
The Patents Act 1952

G.R. CULLEN & CO.

DECLARATION IN SUPPORT OF AN
APPLICATION FOR A PATENT

In support of the Application made for a patent for an invention
entitled:

2-SUBSTITUTED-4-SUBSTITUTED-1,3-DIOXOLANES, SYNTHESIS
AND USE THEREOF

I/We Lawrence R. Wilson

of 10900 Hamon Street
Montreal, Quebec H3M 3A2 CANADA
do solemnly and sincerely declare as follows:-

~~XXXXXX I am/We are the actual inventor(s) of the invention referred to in the basic~~
~~XXXXXX application(s)XXXXXX~~

(or, in the case of an application by a body corporate)

1. I am/We are authorised by
IAF BioChem International, Inc.

the applicant(s) for the patent to make this declaration on its/their behalf.

~~XXXXXX I am/We are the actual inventor(s) of the invention referred to in the basic~~
~~XXXXXX application(s)XXXXXX~~

(or, where a person other than the inventor is the applicant)

2. BERNARD BELLEAU, DILIP DIXIT and NGHE NGUYEN-BA
of 431 Victoria Avenue, Westmont (Quebec) H3Y 2R3, Canada,
3440 Durocher Street, Montreal (Quebec) H2X 2E2, Canada, and
5610 Albanie Avenue, Brossard (Quebec) J4Z 1G6, Canada, respectively

is/are the actual inventor(s) of the invention and the facts upon which the
applicant(s) is/are entitled to make the application are as follows:-

The Applicant is the assignee of the invention from the
inventors.

3. The basic application(s) as defined by Section 141 of the Act was/were made
in U.S.A. on 11.4.88
by BERNARD BELLEAU, DILIP DIXIT and NGHE NGUYEN-BA
in on
by

4. The basic application(s) referred to in paragraph 3 of this Declaration was/
were the first application(s) made in a Convention country in respect of the
invention(s) the subject of the application.

Declared at Montreal this 11th day of May 1989


To: The Commissioner of Patents

Signature of Declarant(s)
Vice President Legal Affairs & Corporate
Secretary

(12) PATENT ABRIDGMENT (11) Document No. AU-B-32644/89
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 631786

- (54) Title
2-SUBSTITUTED-4-SUBSTITUTED-1,3-DIOXALANES, SYNTHESIS AND USE THEREOF
- (51)⁴ International Patent Classification(s)
C07D 405/04 C07D 473/16 C07D 473/18 C07D 473/32
C07D 473/34 C07D 473/40 A61K 031/335 A61K 031/505
- (21) Application No. : 32644/89 (22) Application Date : 11.04.89
- (30) Priority Data
- (31) Number (32) Date (33) Country
179615 11.04.88 US UNITED STATES OF AMERICA
- (43) Publication Date : 12.10.89
- (44) Publication Date of Accepted Application : 10.12.92
- (71) Applicant(s)
BIOCHEM PHARMA INC.
- (72) Inventor(s)
BERNARD BELLEAU; DILIP DIXIT; NGHE NGUYEN-BA
- (74) Attorney or Agent
CULLEN & CO, GPO Box 1074, BRISBANE QLD 4001
- (56) Prior Art Documents
AU 48292/85 C07D 473/18 473/24 473/30
- (57)
2,4 substituted 1,3 - dioxolanes used as
antiviral agents.

CLAIM 1. 1,3-Dioxolane derivatives of the
general formula (L), the geometric and optical isomers
thereof, and mixtures of these isomers:




wherein:

R₁ is selected from the group consisting of
hydrogen, an aliphatic acyl group having 2 to 16
carbon atoms, benzoyl and a benzoyl substituted in any
position by at least one halogen, lower alkyl, lower

(11) AU-B-32644/89
(10) 631786

-2-

alkoxy, nitro and trifluoromethyl groups; R_2 is a heterocyclic radical selected from:



wherein:

R_3 and R_4 are independently selected from the group consisting of hydrogen and lower alkyls; and


R_5 is selected from the group consisting of lower alkyl and halogens.

17. A process for preparing specific 1,3-dioxolane derivatives of formula (L) as defined in Claim 1, substantially as hereinbefore described with reference to Flowsheets I and II.

631786

COMMONWEALTH OF AUSTRALIA

The Patents Act 1952



Name of Applicant(s): Biochem Pharmia Inc
~~IAF BIOCHEM INTERNATIONAL, INC.~~

Address of Applicant(s): 10900 HAMON STREET, MONTREAL
(QUEBEC) H3M 3A2, CANADA

Actual Inventor(s): BERNARD BELLEAU
DILIP DIXIT
NGHE NGUYEN-BA

Address for Service: G.R. CULLEN & COMPANY,
Patent & Trade Mark Attorneys,
Dalgety House,
79 Eagle Street,
Brisbane, Qld. 4000,
Australia.

COMPLETE SPECIFICATION FOR THE INVENTION ENTITLED:

2-SUBSTITUTED-4-SUBSTITUTED-1,3-DIOXOLANES,
SYNTHESIS AND USE THEREOF

The following statement is a full description of the
invention including the best method of performing it known to
us:

2-SUBSTITUTED-4-SUBSTITUTED-1,3-DIOXOLANES,
SYNTHESIS AND USE THEREOF

FIELD OF THE INVENTION


5 The present invention relates to novel
2-substituted-4-substituted-1,3 dioxolanes which are
useful as antiviral agents.

PRIOR ART

10 Retroviral infections are a serious cause
of disease and among others the acquired immuno-
deficiency syndrome (AIDS) is an immunosuppressive
disease associated with life-threatening opportu-
nistic infections and high susceptibility to unusual
neoplasms (Kaposi sarcoma for instance). The human
immunodeficiency virus (HIV) has been recognized as
15 the etiologic agent of AIDS and compounds having an
inhibitory effect against HIV multiplication have
been actively sought.


20 One product which has been proposed for
the treatment of AIDS is the 3'-azido-2'-3'-dide-
oxythymidine commonly referred to as AZT. The
activity of this compound was disclosed by MITSUYA

et al. in Proc. Natl. Acad. Sci., U.S.A. 1985, 82,
7096. The compound has the structure:




This compound is useful in protecting AIDS
carriers against the cytopathogenic effect of the
5 human immunodeficiency virus (HIV) which is the
etiologic agent of AIDS.

Mitsuya et al. have also disclosed in Proc.
Natl. Acad. Sci., U.S.A. 1986, 86, 1911 a group of
2',3'-dideoxynucleosides which appear to possess
10 potent protective activity against HIV-induced cyto-
pathogenicity. A typical such compound is the 2',3'-
dideoxycytidine of the formula:




Balzarini et al. in Biochem. Biophys. Res.
Comm. 1986, 140, 735 disclose that the unsaturated
15 analog of the 2',3'-dideoxycytidine also possesses


antiretroviral effectiveness. This unsaturated analog has the formula:



5 Baba et al. in Biochem. Biophys. Res. Comm. 1987, 142, 128 have described the 2',3'-unsaturated analog of the 2',3'-dideoxythymidine which is a potent selective inhibitor of HIV replication and which corresponds to the formula:





10 Analogues of the 3'-azido-2',3'-dideoxy-thymidine are the 3'-azido-2',3'-dideoxyuridine of the formula:



where y is bromine or iodine. These have been disclosed as having an inhibitory activity against Moloney murine leukemia by T.S. Lin et al., in J. Med. Chem. 1987, 30, 440.

5 Finally, the 3'fluoro analogues of the 2',3'-dideoxycytidine and of the 2',3'-dideoxythymidine have been disclosed by Herdewijn et al. in J. Med. Chem. 1987, 30, 1270 as having potent anti-retroviral activity (anti-HIV). These analogues
10 correspond to the formulae:



The most potent anti-HIV compounds thus far reported are 2',3'-dideoxynucleosides, more particularly, 2',3'-dideoxycytidine (ddCyd) and 3'-azido-2',3'-dideoxythymidine (AzddThd or AZT). These
15 compounds are also active against other kinds of

retroviruses (such as the Moloney murine leukemia virus). It is because of the increasing incidence and the life-threatening characteristics of AIDS that efforts are being expended to discover and
5 develop new non-toxic and potent inhibitors of HIV and blockers of its infectivity.


It is therefore an object of the present invention to provide effective anti-HIV compounds of low toxicity and a synthesis of such new compounds
10 that is readily feasible.

SUMMARY OF THE INVENTION


In accordance with the present invention there is provided novel 2-substituted-4-substituted-1,3-dioxolanes which are particularly useful as anti-
15 viral agents.

More specifically, the novel 2-substituted-4-substituted-1,3-dioxolane derivatives of the present invention correspond to the following formula (L):

(L)



20 wherein R_1 is selected from H, an aliphatic acyl radical from 2 to 16 carbon atoms, a benzoyl which may be substituted in any position by a halogen (bromine, chlorine, fluorine or iodine); a lower alkyl, a lower alkoxy, nitro and trifluoromethyl
25 groups and R_2 is a heterocyclic radical selected from:



wherein R_3 and R_4 are respectively selected from H and a lower alkyl radical having from 1 to 3 carbon atoms, R_4 is an alkenyl radical and R_5 is selected from a lower alkyl or alkenyl radical having from 1 to 3 carbon
 5 atoms or a halogen selected from fluoro and iodo.

Also within the scope of the present invention are the 2,4-disubstituted-1,3-dioxolanes of Formula (L) wherein R_2 could be any nucleoside base analog, those base analogues being known by those of
 10 skill in the art of nucleoside chemistry.

There are two asymmetric carbons (asterisks) in the disubstituted 1,3-dioxolane molecule which provide for two racemic forms ($\pm$) and therefore four optical isomers. These racemates differ in the rela-
 15 tive configurations of the 2- and 4-substituents



which can either assume the cis- and trans-configurations. The use of a graphic representation of the 2,4-disubstituted-1,3-dioxolanes of Formula (L) is meant to include the dl racemic mixture as well as the separate d and l isomers thereof.

Also in accordance with the present invention, there is provided a pharmaceutical composition for administration to persons infected with the AIDS virus or other infectious agent which comprises a therapeutically effective amount of the 2,4-disubstituted dioxolane of Formula (L) or pharmaceutically acceptable salt in association with a pharmaceutically acceptable excipient. The amount of active ingredient which is contained in a single dosage form will vary depending upon the host treated as well as the frequency and the mode of administration.


Also within the scope of the present invention is a method for treating AIDS-infected persons which comprises administering to said persons a therapeutically effective amount of 2,4-disubstituted-1,3-dioxolane of Formula (L). Also within the scope of the present invention is any combination of a 2,4-disubstituted-1,3-dioxolane of Formula (L) with another drug where such combination is therapeutically more advantageous than either drug given above.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of the invention are prepared starting from glycerol and 2-halo- (or an equivalent leaving group such as aryl- or alkyl-sulfonyloxy) acetaldehyde preferably in the form of an acetal derivative according to the reported procedure of E.G. Hallonquist and H. Hibbert, Can. J. Res. 1933, 7, 129. For the purpose of this disclosure, the term acyl is an alkanoyl radical of 2 to 16 carbon atoms, e.g., acetyl, propionyl, isobutyryl, myristoyl,

etc. The compounds of the instant invention are prepared by a total synthesis comprising a few steps. The synthesis is practical and is commercially feasible. The process for preparing one specific compound 5 of the present invention is outlined in the following Flowsheet 1:

Flowsheet 1



The various steps involved in the synthesis illustrated in Flowsheet 1 may be briefly described as follows:

5 Step 1 The primary alcohol function of the starting dioxolane 1 is treated with an oxidizing reagent such as chromic acid (which may be complexed with pyridine) in a compatible organic solvent to give the corresponding dioxolane carboxylic acid II.

10 Step 2 The acid II is converted to a mixed anhydride using an alkyl chloroformate and submitted to a Bayer-Villiger oxidation with an organic peracid such as m-chloroperbenzoic acid to yield the corresponding aroyloxydioxolane III.


15 Step 3 Intermediate III is then reacted with thymine previously silylated with hexamethyldisilazane in a compatible solvent and the reaction catalyzed by a Lewis acid or preferably by trimethylsilyl triflate to give the thymine-1'-yl dioxolane IV.


20 Step 4 The chlorine atom of IV is displaced by reaction with a benzoic acid salt in a compatible solvent such as dimethylformamide to give intermediate V.

25 Step 5 The benzoate ester function is then hydrolyzed under basic conditions to yield the desired end-product VI.

An alternate process for preparing further specific compounds of the present invention is illustrated in Flowsheet II:

FLWSHEET II





The various steps involved in the synthesis illustrated in Flowsheet II may be briefly described as follows:

Step 1 The chlorine atom of starting dioxolane I is displaced by a benzoic (or acetic) acid salt in a solvent such as dimethylformamide to yield the diol monoester VII.

5 Step 2 The hydroxymethyl group of VII is oxidized with a suitable reagent such as chromic acid (which may be complexed with pyridine) in a compatible organic solvent to give the dioxolane carboxylic acid VIII.

10 Step 3 The acid VIII is then submitted to Bayer-Villiger oxidation by the procedure outlined in Step 2 (Flowsheet 1) above to give the corresponding aroyloxy-dioxolane IX.

15 Step 4 The key intermediate IX is reacted with cytosine previously silylated under the reaction conditions outlined in Step 3 (Flowsheet 1) to give the cytosin-1'-yl dioxolane X.

20 Step 5 The amine function of X is acylated with acetic anhydride in pyridine to give XI which provides for easier separation of isomers.

Step 6 The ester and acetyl functions of XI are hydrolyzed under basic conditions to yield the desired end-product XII.

25 Step 7 (IX to XIII) Key intermediate IX is reacted with adenine by the procedure outlined above in Step 3 (Flowsheet 1) to give XIII.

Step 8 (XIII to XIV) The ester function of XIII is hydrolyzed under basic conditions to yield the desired end-product XIV.

30 Step 9 (IX to XV) Intermediate IX is reacted with 2-amino-6-chloropurine under the conditions outlined in Step 3 (Flowsheet 1) to give compound XV).

35 Step 10 (XV to XVI) The preceding intermediate is hydrolyzed under basic conditions to yield the desired end-product XVI.

Step 11 (XVI to XVII) The chlorine atom of XVI is removed by catalytic hydrogenation over Pd/C to give the 2'-amino-purin-9'-yl dioxolane XVII.

Step 12 The above intermediate XV is reacted with
5 excess ammonia under pressure whereupon the 2',6'-diamino-purin-9'-yl dioxolane XVIII is generated.

Step 13 Compound XVI is submitted to boiling sodium hydroxide to give the desired end-product guanin-9'-yl dioxolane XIX.

10 ANTIVIRAL ACTIVITY

All of the compounds of the preferred embodiments are novel and some are valuable for their properties as non-toxic inhibitors of the primary replication of HIV-1 in previously uninfected T-lymphocytes over
15 a prolonged period of time.

In particular, the compounds having the formula XII possess desirable properties, i.e., antagonism of HIV infectivity towards T-lymphocytes in the absence of cytotoxicity.

20 In vitro testing was conducted on the compounds to determine their inhibitory properties. Table 1 represents the results of a typical experiment. The figures reported are the micromolar concentrations in the incubation media which affect the
25 ability of T-lymphocyte H-9 cells to be infected by HIV-1 following the protocol of H. Mitsuya and S. Broder, Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 1911-1915; the level of infection being measured by the level of reverse transcriptase activity (RTA) as
30 assayed in the usual manner with tritiated thymidine triphosphate (TTP). As a control drug, 2',3'-dideoxy-3'azido-thymidine (AZT) was used and the RTA measured in the incubation medium after 8, 12 and 26 days of exposure to the inhibitor. The values in Table 1
35 reflect the total number of virus particles in the incubation medium.

Table 1

Example of the effects to prototype compounds trans-XII, cis-XIV and AZT on ability of H-9 cells to be infected by HIV-1.

		RTA activity (cpm) after:				
	<u>Expt.#</u>	<u>Inhibitor</u>	<u>Conc.-</u>	<u>8 days</u>	<u>12 days</u>	<u>26 days</u>
5	1	none	-	198,612	327,570	239,019
		<u>trans-XII</u>	10μM	4,608	83,462	312,478
		<u>trans-CII</u>	50μM	1,319	758	1,732
		<u>AZT</u>	20μM	633	419	821
10	2	none	-	64,769	119,580	227,471
		<u>cis-XIV</u>	20μM	2,618	130,563	210,583
		<u>cis-XIV</u>	50μM	1,132	39,752	231,609
		<u>AZT</u>	20μM	587	1,316	679

It is apparent from the table that prototype compound trans-XII exhibits potent inhibitory activity. Other analogues displayed variable degrees of antiviral activity. Accordingly, as it is the rule for certain analogues of nucleosides, trans-XII and selected analogues are expected to demonstrate in vivo activity as inhibitors of retroviruses. Such compounds may also be used in combination with other antiviral agents at reduced doses, thus lowering their toxicity potential.

25 TOXICITY

In contrast to the results obtained with AZT or with other di-deoxynucleosides analogues, in vitro toxicity experiments showed that the compound trans-XII is non toxic even at concentration as high as 200μM. In spite of the AZT activity, its serious bone marrow toxicity limits its therapeutic usefulness. It is then highly desirable to provide with new active antiviral agents which would be devoided of toxic side effects.

EXAMPLES

Example 1. Preparation of 2-chloromethyl-1,3-dioxolane-4-carboxylic acid (II).

Starting material I (40 g; prepared according to E.G. Hallonquist and H. Hibbert, Can. Res. J. 1933, 7, 129) was treated with pyridinium dichromate (PDC; 345 g) in dimethyl formamide (DMF; 690ml) at 0° according to the procedure of E.J. Corey and G. Schmidt, Tetrahedron Lett., 1979, 399 and product II obtained as a crude mixture of cis- and trans-isomers (20 g) was identified by its ¹H NMR spectrum [200 MHz, CDCl₃; tetramethyl silane (TMS) as internal reference]

δ(ppm): 3.6-3.8 (m, 2H; CH₂Cl);
 4.1-4.5 (m, 2H; C₅H₂);
 4.72-4.797 (qq, 1H; C₄-H);
 5.29-5.46 (tt, 1H; C₂-H).

The product was used as such in the next step.

Example 2. Preparation of 2-chloromethyl-4-m.chlorobenzoyloxy-1,3-dioxolane (III).

The preceding product II (5.26 g) was treated in CH₂Cl₂ at -20° with 3.6 ml of ethyl chloroformate in the presence of 4.5 of triethylamine. To the solution was added 8.85 g of m.chloroperbenzoic acid at room temperature according to the procedure of D.H.R. Barton, I.H. Coates and P.G. Sammes, J. Chem. Soc., Perkin 1, 1973, 599 to give III as a mixture of cis- and trans-isomers. These were separated and purified by flash chromatography on silica gel using a mixture of hexanes and ethyl acetate as the eluent. The isomers were identified by their ¹H NMR spectra (recorded as in example 1):

trans-isomer of III: δ (ppm):

- 3.66 (q, 2H; $\text{CH}_2\text{-Cl}$);
4.36 (qq, 2H; $\text{C}_5\text{-H}_2$);
5.57 (t, 1H; $\text{C}_2\text{-H}$);
5 6.7 (q, 1H; $\text{C}_4\text{-H}$);
7.39-8.0 (m, 4H; aromatic H);

cis-isomer of III: δ (ppm):

- 3.66 (q, 2H; CH_2Cl);
4.24 (qq, 2H; $\text{C}_5\text{-H}_2$);
10 5.43 (t, 1H; $\text{C}_2\text{-H}$);
6.63 (q, 1H; $\text{C}_4\text{-H}$);
7.42-8.04 (m, 4H; aromatic H).

Example 3. Preparation of 2-chloromethyl-4-(thymine-1'-yl)-1,3-dioxolane (IV).

- 15 Reaction of the preceding compound with
thymine was carried out according to the procedure
of D.S. Wise and L.B. Townsend, in Nucleic Acid
Chemistry, Eds. L.B. Townsend and R.S. Tipson, John
Wiley & Sons, Inc., New York, 1978, Part 1,
20 pp. 413-419. The product was a mixture of cis- and
trans-isomers of IV (37.3 mg from 131 mg of III)
which had the following ^1H NMR characteristics
(obtained as in example 1):

- δ (ppm): 1.93 (d, 3H; $5'\text{-CH}_3$);
25 3.64 and 3.85 (dd, 2H; CH_2Cl);
4.17-4.46 (m, 2H; $\text{C}_5\text{-H}_2$);
5.26 and 5.72 (tt, 1H; $\text{C}_2\text{-H}$);
6.6 and 6.66 (qq, 1H; $\text{C}_4\text{-H}$);
7.40 and 7.49 (dd, 1H; $\text{C}_6\text{-H}$);

- 30 U.V.: (CH_3OH) λ_{max} . 264 nm.

Example 4. Preparation of 2-acetoxymethyl-4-(thymine-1'-yl)-1,3-dioxolane (V).

- The preceding compound IV (35 mg) was
reacted with anhydrous potassium acetate (70 mg) in
35 boiling DMF (3 ml) for 4h to give after conventional

workup a cis- and trans-mixture of V (25 mg). These isomers were purified and separated by flash chromatography on silica using a mixture of hexanes and ethyl acetate as the eluent. Their ^1H NMR spectra were as follows:

trans-isomer of V: δ (ppm):

- 1.94 (d, 3H; C_5 , $-\text{CH}_3$);
- 2.12 (s, 3H; CH_3CO_2 -);
- 4.05-4.43 (m, 4H; C_2 - CH_2 - O_2CCH_3 and C_5 - H_2);
- 5.65 (t, 1H; C_2 - H);
- 6.31 (q, 1H; C_4 - H);
- 7.14 (d, 1H; C_6 , $-\text{H}$);
- 8.18 (m, 1H; N_3 , $-\text{H}$).

cis-isomer of V: δ (ppm):

- 1.97 (d, 3H; C_5 , CH_3);
- 2.14 (s, 3H; $\text{CH}_3\text{CO-O}$);
- 4.13-4.49 (m, 4H; 2- $\text{CH}_2\text{OCOCH}_3$ and C_5 - H_2);
- 5.19 (t, 1H; C_2 - H);
- 6.40 (q, 1H; C_4 - H);
- 7.43 (d, 1H; C_6 , $-\text{H}$);
- 8.12 (m, 1H; N_3 , $-\text{H}$).

U.V.: (CH_3OH) λ_{max} 264 nm.

Example 5. Preparation of 2-hydroxymethyl-4-(thymine-1'-yl)-1,3-dioxolane (VI).

The preceding trans- and cis-isomers of V (10 mg) were respectively treated with a catalytic amount of potassium carbonate in methanol (5 ml) at room temperature for 5-6 h and the mixture worked up in the usual manner and the respective products purified by flash chromatography on silica gel using a mixture of ethyl acetate and methanol as the eluent. The ^1H NMR spectrum of the pure trans-isomer of VI was as follows (in CD_3COCD_3 as solvent);

trans-VI: δ (ppm):

- 1.87 (d, 3H; C₅, -CH₃);
3.61 (q, 2H; C₂-CH₂OH);
4.30 (qq, 2H; C₅-H₂);
5.56 (t, 1H; C₂-H);
6.31 (q, 1H; C₄-H);
7.41 (d, 1H; C₆, H).

U.V.: (CH₃OH) λ_{max} . 265 nm.

cis-isomer of VI (in CD₃COCD₃): δ (ppm):

- 1.82 (d, 3H; C₅, -CH₃);
3.82 (q, 2H; C₂CH₂OH);
4.24 (qq, 2H; C₅-H₂);
5.02 (t, 1H; C₂-H);
6.34 (q, 1H; C₄-H);
7.81 (d, 1H; C₆, -H).

U.V.: (CH₃OH) λ_{max} . 264nm.

Example 6. Preparation of 2-benzoyloxymethyl-4-hydroxymethyl-1,3-dioxolane (VIII).

Starting material 1 (41.6) was treated with potassium benzoate (65.56 g) in boiling dimethyl formamide containing 100 mg of 18-crown-6 for 24 h after which time the mixture was worked up in the usual manner and the product (51.02 g) characterized by its ¹H NMR spectrum (CDCl₃; TMS):

- δ (ppm): 3.5-4.8 (m, 7H; C₅-H₂; C₂-CH₂OCOC₆H₅, C₄-CH₂OH and C₂-H);
5.05 and 5.16 (tt, 1H; C₄-H);
7.27-8.10 (m, 5H; aromatic H).

Similar results were obtained using potassium acetate instead of potassium benzoate.

Example 7. Preparation of 2-benzoyloxymethyl-1,3-dioxolane-4-carboxylic acid (VIII).

The preceding compound VII (51.02 g) was treated at 0° with pyridinium dichromate (282.5 g) in dimethyl formamide (565 ml) and the mixture worked

up in the usual manner to give 35 g of crude VIII which was used as such in the next example.

Example 8.

A 10 g portion of crude VIII was treated with 6.03 ml of ethyl chloroformate in the presence of 8.6 ml of triethylamine followed by the addition of 16.81 g of m.chloroperbenzoic acid exactly as described in example 2 for the case of the preparation of intermediate III. The isomers of product IX thus obtained were purified by flash chromatography on silica gel using a mixture of hexanes and ethyl acetate as the eluent. They were characterized by their ^1H NMR spectra (CDCl_3);

trans-isomer of IX: $\delta(\text{ppm})$:

4.29 (qq, 2H; $\text{C}_5\text{-H}_2$);
4.49 (d, 2H; $\text{C}_2\text{-CH}_2\text{OCOC}_6\text{H}_5$);
5.66 (t, 1H; $\text{C}_2\text{-H}$);
6.70 (q, 1H; $\text{C}_4\text{-H}$);
7.27-8.10 (m, 9H; aromatic)

cis-isomer of IX: $\delta(\text{ppm})$:

4.27 (qq, 2H; $\text{C}_5\text{-H}_2$);
4.51 (d, 2H; $\text{C}_2\text{-CHOCOC}_6\text{H}_5$);
5.51 (t, 1H; $\text{C}_2\text{-H}$);
6.59 (d, 1H; $\text{C}_4\text{-H}$);
7.26-8.09 (m, 9H; aromatic).

Example 9. Preparation of 2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-dioxolane (X).

Following the procedure described by T. Ueda and S.I. Watanabe, Chem. Pharm. Bull. (Japan), 1985, 33, 3689-3695 and by G. Gosselin, M.C. Bergogne, J. DeRudder, E. DeClercq and J.L. Imbach, J. Med., Chem, 1987, 30, 982-991, cytosine (139 mg) and either isomer of the preceding compound IX (363 mg) yielded a mixture of cis- and trans-isomers (390 mg) X which were used as such in the following step.

Example 10.

Treatment of cis- and trans-X with excess acetic anhydride in pyridine at room temperature yielded after work up in the conventional manner, a mixture of the cis- and trans-isomers of XI which were separated and purified by flash chromatography on silica gel using a mixture of hexanes and ethyl acetate as the eluent. They were characterized by their ^1H NMR spectra (CDCl_3):

10 trans-isomer of XI: $\delta(\text{ppm})$:

2.15 (s, 3H; C_4 , -NH-COCH $_3$);
4.16 and 4.46 (m, 4H; C_5 -H $_2$ and C_2 -CH $_2$ OCOC $_6$ -H $_5$);
5.96 (t, 1H; C_2 -H);
15 6.24 (q, 1H; C_4 -H);
7.55-8.09 (m, 5H; aromatic);
8.15 (d, 1H; C_6 , -H)

cis-isomer of XI: $\delta(\text{ppm})$:

2.15 (s, 3H; C_4 , -NH-COCH $_3$);
20 4.26 and 4.56 (m, 4H; C_5 -H $_2$ and C_2 -CH $_2$ OCOC $_6$ -H $_5$);
5.35 (t, 1H; C_4 -H);
6.25 (q, 1H; C_4 -H);
7.18 (d, 1H; C_5 , -H);
25 7.58-8.04 (m, 5H; aromatic)
8.17 (d, 1H; C_6 , -H).

Example 11. Preparation of cis- and trans-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-dioxolane (XII).

Each of the preceding isomers of XI (25 mg) was treated with potassium carbonate (20 mg) in methanol at room temperature for several hours and the mixtures worked in the usual manner to yield each isomer of XII which were epurified by chromatography on silica gel using a mixture of ethyl acetate and methanol as an eluent. They were crystalized from

methanol and characterized by their respective ^1H NMR spectra (DC_3COCD_3):

trans-isomer of XII: $\delta(\text{ppm})$:

- 5 m.p. 179-180° 3.62 (q, 2H; $\text{C}_2\text{-CH}_2\text{OH}$);
4.21 (qq, 2H; $\text{C}_5\text{-H}_2$);
5.50 (t, 1H; $\text{C}_2\text{-H}$);
5.93 (d, 1H; $\text{C}_5\text{-H}$, $J=7.5\text{Hz}$);
6.18 (q, 1H; $\text{C}_4\text{-H}$);
7.66 (d, 1H; $\text{C}_6\text{-H}$, $J=7.5\text{Hz}$).

10 U.V.: (CH_3OH) λ_{max} 271 nm.

cis-isomer of XII: $\delta(\text{ppm})$:

- 3.82 and 4.15 (m, 4H; $\text{C}_5\text{-H}_2$ and $\text{C}_2\text{-CH}_2\text{OH}$);
m.p. 173-174° 5.04 (t, 1H; $\text{C}_2\text{-H}$);
5.83 (d, 1H; $\text{C}_5\text{-H}$);
15 6.23 (q, 1H; $\text{C}_4\text{-H}$);
8.05 (d, 1H; $\text{C}_6\text{-H}$);

U.V.: (CH_3OH) λ_{max} 270 nm.

Example 12. Preparation of 2-benzoyloxymethyl-4-(adenin-9'-yl)-1,3-dioxolane (XIII).

- 20 Following the same procedure as in example 9, adenosine (135 mg) was coupled with either isomer of intermediate IX (545 mg) in dimethylformamide at 120° in the presence of trimethylsilyl triflate (0.45 ml) and the mixture worked up in the usual manner to
- 25 yield a mixture of cis- and trans-isomers of XIII (540 mg) which were purified and separated by chromatography on silica gel using a mixture of hexanes and ethyl and acetate as the eluent. They were characterized by their respective ^1H NMR spectra (CDCl_3):

30 trans-isomer of XIII: $\delta(\text{ppm})$:

- 4.5 and 4.59 (m, 4H; $\text{C}_5\text{-H}_2$ and $\text{C}_2\text{-CH}_2\text{OCOC}_6\text{H}_5$);
6.00 (t, 1H; $\text{C}_2\text{-H}$);
6.65 (q, 1H; $\text{C}_4\text{-H}$);
6.75 (m, 2H; $\text{C}_6\text{-H}_2$);
35 7.68-8.21 (m, 5H; aromatic);
8.36 (s, 1H; $\text{C}_2\text{-H}$);
8.37 (s, 1H; $\text{C}_8\text{-H}$).

cis-isomer of XIII: δ (ppm):

- 4.62 (d, 2H; C_2 -CH₂OCOC₆H₅);
- 4.65 (qq, 2H; C_5 -H₂);
- 5.52 (t, 1H; C_2 -H);
- 5 6.59 (q, 1H; C_4 -H);
- 6.85 (m, 2H; C_6 , -NH₂);
- 6.96-7.71 (m, 5H; aromatic);
- 7.66 (d, 2H; C_2 , -H and C_8 , -H).

Example 13. Preparation of 2-hydroxymethyl-4-(adenin-9'-yl)-1,3 dioxolane (XIV).

Each isomer of the preceding compound XIII was treated with potassium carbonate in methanol at room temperature by the same procedure described in example 5 and each product purified by column chromatography on silica gel using a mixture of ethyl acetate and methanol as the eluent. The isomers were further purified by crystallization from methanol and characterized by their ¹N NMR spectra (CD₃SOCD₃):

trans-isomer of XIV: δ (ppm):

- 20 3.50 (d, 2H; C_2 -CH₂OH);
- 4.70 (m, 2H; C_5 -H₂);
- 5.52 (t, 1H; C_2 -H);
- 6.44 (q, 1H; C_4 -H);
- 8.18 (s, 1H; C_2 , -H);
- 25 8.31 (s, 1H; C_8 , -H).

U.V.: (CH₃OH) λ_{max} . 269 nm.

cis-isomer of XIV: δ (ppm):

- 4.63 (d, 2H; C_2 -CH₂OH);
- 4.29 (qq, 2H; C_5 -H₂);
- 30 5.08 (t, 1H; C_2 -H);
- 6.43 (q, 1H; C_4 -H);
- 8.18 (s, 1H; C_2 , -H);
- 8.36 (s, 1H; C_8 , -H).

U.V.: (CH₃OH) λ_{max} . 269 nm.

Example 14. Preparation of 2-benzoyloxymethyl-4-(2'-amino-6'-chloro-purin-9'-yl)-1,3-dioxolane (XV).

A solution of 2-amino-6-chloropurine (600 mg; 3.54 mmol) in 20 ml of hexamethyldisilazane (HMDS) containing 0.5 ml of trimethylsilyl chloride (TMS-Cl) was heated under reflux for 3 h after which time the mixture was evaporated to dryness in vacuo. The residue was dissolved in 75 ml of dichloroethane containing 910 mg of compound IX and 0.6 ml of trimethylsilyl triflate (TMS- T_f) added. After refluxing under argon for 4 h, the mixture was collected, 2 g of solid $NaHCO_3$ added followed by 50 ml of saturated aqueous $NaHCO_3$. The organic layer was collected and after work-up in the usual manner, crude XV was obtained as an oil which was purified and separated into its isomer by chromatography on silica gel using hexane-ethyl acetate (3:7) as the eluent to give 230 mg of pure trans- and 250 mg of pure cis-isomer as colorless foams. They were characterized by their 1H NMR spectra ($CDCl_3$):

trans-isomer of XV (R : 0.40; hexane-EtOAc 3:7):

δ (ppm): 4.45-4.52 (m, 4H; $C_5-H_2, C_2-CH_2OCOC_6H_5$);
5.16 (b, 2H; C_2-NH_2);
5.83 (t, 1H; $C_2-H, J=3.8$ Hz);
6.39 (dd, 1H; C_4-H);
7.41-7.58 (m, 3H; aromatic);
7.92 (s, 1H; C_8-H);
8.06 (d, 2H; aromatic, $J=7$ Hz).

U.V.: (CH_3OH) λ_{max} . 312 nm.

cis-isomer of XV (R : 0.26, hexane-EtOAc 3:7):

5 δ (ppm): 4.25-4.33 (dd, 1H; C₅-H, J=5.43 Hz);
 4.59-4.64 (m, 3H; C₅-H and C₂-CH₂-OCOC₆H₅);
 5.17 (b, 2H; C₂, -NH₂);
 5.42 (t, 1H; C₂-H, J=3.50 Hz);
 6.33-6.53 (dd, 1H; C₄-H);
 7.38-7.57 (m, 3H; aromatic);
 7.93-7.98 (d, 2H; aromatic);
 8.00 (s, 1H; C₈, -H).

U.V.: (CH₃OH) λ_{max} .312 nm.

10 Example 15. Preparation of trans- and cis-2-hydroxymethyl-4-(2'-amino-6'-chloro-purin-9'-yl)-1,3-dioxolane (XVI).

15 The preceding trans-isomer of XV (180 mg) was dissolved in 30 ml of methanol, the solution cooled to 0° and dry ammonia bubbled through for 15 min. After stirring at room temperature for 15 h, the solvent was removed in vacuo and the residue crystallized from ether. After recrystallization from ethanol-ether, 98 mg of pure trans-XVI, m.p.
 20 155-156°, was obtained (R_f: 0.23, EtOAc). It was characterized by ¹H NMR (DMSO-d₆):

trans-XVI: δ (ppm): 3.44-3.49 (m, 2H; C₂-CH₂OH);
 4.37-4.45 (m, 2H; C₅-H₂);
 5.01 (t, 1H; C₅-CH₂OH, J=6.2Hz);
 5.46 (t, 1H; C₂-H, J=3.6 Hz);
 6.27-6.32 (dd, 1H; C₄-H, J=4, 1 Hz);
 7.00 (b, 2H; C₂, -NH₂);
 8.26 (s, 1H; C₈, -H).

U.V.: (CH₃OH) λ_{max} .247 and 308 nm.

30 The cis-isomer of XVI was obtained in similar yield from the cis-isomer of XV by the same preceding procedure. After recrystallization from ethanol-ether, the pure product had m.p. 145-147° (R_f:0.24, EtOAc). It was characterized by ¹H NMR (DMSO-d₆):

- cis-XVI: δ (ppm): 3.54-3.59 (m, 2H; C₂-CH₂OH);
 4.12-4.19 (dd, 1H; C₅-H, J=5.3 Hz
 and 9.8 Hz);
 4.48-4.53 (d, 1H; C₅-H, J=9.8 Hz);
 5.01 (t, 1H; C₂-H, J=2.8 Hz);
 5.09 (t, 1H; C₂-CH₂-OH, J=6.0 Hz);
 6.24 (d, 1H; C₄-H, J=5.1 Hz);
 6.96 (b, 2H; C₂, -NH₂);
 8.23 (s, 1H; C₈, -H).
 10 U.V.: (CH₃OH) λ_{max} . 247 and 308 nm.

Example 16. Preparation of trans-and cis-2-hydroxy-methyl-4-2'-amino-purin-9'-yl)-1,3-dioxolane (XVII).

- The preceding trans-isomer of XVI (50 mg) was submitted to hydrogenation conditions under 50 psi of hydrogen over 10% Pd/C (30 mg) in 30 ml of ethanol containing 0.5 ml of triethylamine. After 3 h of shaking, the mixture was worked up in the usual manner to yield a solid which was recrystallized from ethanol-ether to give 36 mg of pure trans-XVII, m.p. 153-155°, R_f: 0.25 (EtOAc: MeOH 85:15). It was characterized by ¹H NMR (DMSO-d₆):

- trans-XVII: δ (ppm): 3.44-3.49 (m, 2H; C₂-CH₂OH);
 4.38-4.44 (m, 2H; C₅-H₂);
 4.99 (t, 1H; C₂-CH₂-OH, J=6.1 Hz);
 5.45 (t, 1H; C₂-H, J=3.6 Hz);
 6.29-6.34 (dd, 1H; C₄-H);
 6.59 (b, 2H; C₂, -NH₂);
 8.19 (s, 1H; C₈, -H);
 8.59 (s, 1H; C₆, -H).

- 30 The cis-isomer of XVII was obtained in similar yield from the cis-isomer of XVI by the same preceding procedure. After recrystallization from ethanol-ether, the pure product had m.p. 145-148°, R_f: 0.25 (EtOAc: MeOH 85:15). It was characterized by ¹H NMR
 35 (DMSO-d₆):

cis-XVII: δ (ppm): 3.55-3.60 (dd, 2H; C₂-CH₂H, J=2.10 and 6.1 Hz);
 4.14-4.22 (dd, 1H; C₅-H, J=5.4 and 9.7 Hz);
 5 4.47-4.53 (dd, 1H; C₅-H, J=1.38 and 9.7 Hz);
 5.02 (t, 1H; C₂-H, J=3 Hz);
 5.11 (t, 1H; C₂-CH₂OH, J=7.2 Hz);
 6.58 (b, 2H; C₂-NH₂);
 10 8.19 (s, 1H; C₈, -H);
 8.57 (s, 1H; C₆, -H).
 U.V.: (CH₃OH) λ_{max} . 255, 308 nm.

Example 17. Preparation of trans- and cis-2-hydroxy-methyl-4-(2',6'-diamino-purin-9'-yl)-1,3-dioxolane (XVIII):

The above compound trans-XV (200 mg) was dissolved in 30 ml of methanol saturated at 0° with dry ammonia and the solution heated in a steel bomb to 105-110° for 16h. The solution was evaporated to dryness and the residue purified by chromatography on silica gel using chloroform-methanol 4:1 as the eluent to give 101 mg of product which was recrystallized from methanol-ether to yield pure trans-XVIII, m.p. 165-168°, R_f:0.30(CHCl₃;CH₃OH 4:1). It was characterized by ¹H NMR (DMSO-d₆):

trans-XVIII: δ (ppm): 3.43-3.48 (m, 2H; C₂-CH₂OH);
 4.34-4.49 (m, 2H; C₅-H₂);
 4.97 (t, 1H; C₂-CH₂OH);
 5.42 (t, 1H; C₂-H);
 5.82 (b, 2H; C₂, -or C₆, -NH₂);
 6.18-6.23 (dd, 1H; C₄-H);
 6.72 (b, 2H; C₂, - or C₆, -NH₂);
 7.84 (s, 1H; C₈, -H).

U.V.: (CH₃OH) λ_{max} . 255, 280 nm.

The cis-isomer of XVIII was obtained by the same preceding procedure from compound cis-XV. After

recrystallization from methanol-ether, pure cis-XVIII, m.p. 180-182°, R_f :0.32(CHCl_3 - CH_3OH 4:1) was obtained in a similar yield. It was characterized by ^1H NMR ($\text{DMSO}-d_6$):

- 5 cis-XVIII: δ (ppm): 3.56-3.58 (d, 2H; C_2 - CH_2OH , $J=4.2\text{Hz}$);
 4.11-4.19 (dd, 1H; C_5 - H , $J=4.5$ and 9.7Hz);
 4.38-4.44 (dd, 1H; C_5 - H , $J=1.6$ and 11.2Hz);
 10 5.00 (t, 1H; C_2 - H , $J=3.1\text{ Hz}$);
 5.91 (b, 2H; C_2 , - or C_6 , - NH_2);
 6.15-6.19 (dd, 1H; C_4 - H);
 6.84 (b, 2H; C_2 , - or C_6 , - NH_2);
 7.86 (s, 1H; C_8 , - H).
 15 U.V.: (CH_3OH) λ_{max} .254, 279 nm.

Example 18. Preparation of cis- and trans-2-hydroxy-methyl-4-(guanosin-9'-yl)-1,3-dioxolane (XIX).

- 20 The above cis-XVI (40 mg) was dissolved in a mixture of 15 ml of methanol, 2 ml of water and 2 g of sodium hydroxide and the solution heated under reflux for 5 h after which time it was diluted with 100 ml of water and excess pyridinium sulfonate resin added. The slurry was filtered, the resin washed
 25 with water and the combined aqueous filtrates evaporated to dryness in vacuo to leave a residue which was taken up in 50% aqueous methanol. The solution was treated with activated charcoal, filtered and the filtrate evaporated to dryness in vacuo to give a solid residue that was recrystallized from ethanol-
 30 water to yield pure cis-XIX (27 mg) m.p. > 250° decomp., R_f :0.23 (CHCl_3 : CH_3OH 7:3). It was characterized by ^1H NMR ($\text{DMSO}-d_6$):

cis-XIX: δ (ppm): 3.55 (m, 2H; C₂CH₂OH);
 4.10-4.17 (dd, 1H; C₅-H, J=5.6 and
 9.8 Hz);
 4.37-4.42 (dd, 1H; C₅-H, J=1.4 and
 9.6 Hz);
 4.98 (t, 1H; C₂-H, J=3.2 Hz);
 5.15 (b, 1H; C₂-CH₂OH);
 6.10-6.13 (dd, 1H; C₄-H, J=2.4 and
 5.3 Hz);
 6.66 (b, 2H; C₂, -NH₂);
 7.78 (s, 1H; C₈, -H);
 11.02 (b, 1H; N₁, -H).

U.V.: (CH₃OH) λ_{max} .252, 270(shoulder).


The isomer trans-XIX was obtained in similar yeild
 from the above trans-XVI by the same preceding pro-
 cedure. After recrystallization from ethanol-water,
 pure trans-XIX, m.p. > 260°(dec.), R_f:0.23
 (CHCl₃:CH₃OH 7:3) was obtained and characterized by
¹H NMR (DMSO-d₆):

trans-XIX: δ (ppm): 3.42-3.47 (m, 2H; C₂-CH₂OH);
 4.34 (d, 2H; C₅-H₂, J=4.8Hz);
 4.99 (t, 1H; C₂-CH₂OH);
 5.40 (t, 1H; C₂-H, J=3.5 Hz);
 6.15-6.20 (t, 1H; C₄-H, J=4.8 Hz);
 6.49 (b, 2H; C₂, -NH₂);
 7.83 (s, 1H; C₈, -H);
 10.64 (b, 1H; N₁, -H).

U.V.: (CH₃OH) λ_{max} .252, 270 (shoulder)

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-


1. 1,3-Dioxolane derivatives of the general formula (L), the geometric and optical isomers thereof, and mixtures of these isomers:



wherein:

R_1 is selected from the group consisting of hydrogen, an aliphatic acyl group having 2 to 16 carbon atoms, benzoyl and a benzoyl substituted in any position by at least one halogen, lower alkyl, lower alkoxy, nitro and trifluoromethyl groups; R_2 is a heterocyclic radical selected from:





wherein:

R_3 and R_4 are independently selected from the group consisting of hydrogen and lower alkyls; and

R_5 is selected from the group consisting of lower alkyl and halogens.

2. The compound of Claim 1 which is the 2-acetoxymethyl-4-(thymine-1'-yl)-1,3-dioxolane.

3. The compound of Claim 1 which is the 2-hydroxymethyl-4-(thymine-1'-yl)-1,3-dioxolane.

4. The compound of Claim 1 which is the 2-benzoyloxymethyl-4-(cytosine-1'-yl)-1,3 dioxolane.

5. The compound of Claim 1 which is the trans-2-hydromethyl-4-(cytosine-1'-yl)-1,3-dioxolane.



6. The compound of Claim 1 which is the 2-benzoyloxymethyl-4-(adenin-9'-yl)-1,3-dioxolane.

7. The compound of Claim 1 which is the 2-hydroxymethyl-4-(adenin-9'-yl)-1,3-dioxolane.

8. The compound of Claim 1 which is the 2-benzoyloxymethyl-4-(2'-amino-6'-chloro-purin-9'-yl)-1,3-dioxolane.

9. The compound of Claim 1 which is the 2-hydroxymethyl-4-(2'-amino-6'-chloro-purin-9'-yl)-1,3-dioxolane.

10. The compound of Claim 1 which is the 2-hydroxymethyl-4-(2'-amino-purin-9'-yl)-1,3-dioxolane.


11. The compound of Claim 1 which is the 2-hydroxymethyl-4-(2',6'-diamino-purin-9'-yl)-1,3-dioxolane.

12. The compound of Claim 1 which is the 2-hydroxymethyl-4-(guanin-9'-yl)-1,3-dioxolane.

13. A method for treating viral infections by administering to an infected host a therapeutically effective amount of a compound of a 2-substituted-4-



substituted-1,3-dioxolane of Formula (L), the geometric and optical isomers thereof, and mixtures of these isomers:




(L)

wherein:

R_1 is selected from the group consisting of hydrogen, an aliphatic acyl group having 2 to 16 carbon atoms, benzoyl and a benzoyl substituted in any position by at least one halogen, lower alkyl, lower alkoxy, nitro and trifluoromethyl groups;

R_2 is a heterocycle radical selected from:





R_3 and R_4 are independently selected from the group consisting of hydrogen and lower alkyls; and

R_5 is selected from the group consisting of lower alkyls and halogens.

14. A method for treating viral infections as claimed in claim 13 wherein the compound administered is a compound as defined in any one of claims 2-12.

15. A pharmaceutical composition which comprises a therapeutically effective amount of a 1,3-dioxolane derivative of the general formula (L) as defined in claim 1, or the geometric or optical isomer thereof, or mixtures of these isomers, or the pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient.

16. A pharmaceutical composition as claimed in Claim 15 wherein the 1,3-dioxolane derivative is a derivative as defined in any one of Claims 2-12.

17. A process for preparing specific 1,3-dioxolane derivatives of formula (L) as defined in Claim 1, substantially as hereinbefore described with reference to Flowsheets I and II.

DATED this 3rd day of September 1992

BIOCHEM PHARMA INC

By their Patent Attorneys

CULLEN & CO.

